SOL-001

Soley Therapeutics has pulled in $200 million via a series C financing as the company advances its two lead oncology assets towards the clinic and continues to investigate its stress-reducing drug candidates for neurodegenerative disorders and metabolic diseases. The funding round announced Wednesday included existing investors Breyer Capital and GordonMD Global Investments, along with new backers Surveyor Capital, HRTG Partners and RWN Management.Founded in 2020 as a University of California spinout, Solely is using its platform to translate the cellular information of stress biology into mechanistic insights, in the hope of revealing novel drug candidates that otherwise would be missed. The platform captures time-resolved responses across thousands of features in human cells, with this data then used — in conjunction with AI and machine learning models —  to accelerate hit finding, mechanistic insights and molecule design."We built Soley to measure how living human cells, in health and disease, respond to drug exposure and determine their fate," explained CEO and co-founder Yerem Yeghiazarians. "We then translate this cellular information into a robust portfolio of novel drug candidates across a broad range of disease areas and indications."The new financing — following earlier series A and B rounds totalling $90 million — will support Soley's two lead oncology assets, SOL-001 and SOL-002. The lead asset for acute myeloid leukaemia is on track for IND filing this year, while the second candidate for solid tumours is entering IND-enabling studies.While these compounds are designed to selectively intensify stress signals within cancer cells, the firm's efforts outside oncology are focused on stress reversal and diseases marked by cellular exhaustion or stress dysregulation. Work in this area aims to find therapeutic compounds and mechanisms that restore healthier cell states resilience in neurodegenerative diseases, obesity and hair regeneration.